18889881171
Kalkine 0
countryflagUS

BioMark Diagnostics Inc

Healthcare US BMKDF

0.1899USD
-(-%)

Last update at 2025-05-16T13:30:00Z

Day Range

0.190.19
LowHigh

52 Week Range

0.120.23
LowHigh

Fundamentals

  • Previous Close 0.19
  • Market Cap14.45M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.86261M
  • Revenue TTM0.16M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.04M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -1.84223M -1.45390M -1.09419M -1.21528M -0.54561M
Minority interest - - - - 0.00000M
Net income -1.84223M -1.45390M -1.09419M -1.21528M -0.54561M
Selling general administrative 1.15M 0.86M 0.96M 1.42M 0.49M
Selling and marketing expenses - - - - -
Gross profit 0.15M 0.04M - 0.26M 0.00000M
Reconciled depreciation 0.39M 0.18M 0.01M 0.01M -
Ebit -1.73200M -1.40311M -1.08258M -1.20268M -0.52686M
Ebitda -1.34580M -1.22348M -1.06890M -1.19077M -0.54561M
Depreciation and amortization 0.39M 0.18M 0.01M 0.01M -
Non operating income net other - - - - 0.00000M
Operating income -1.73200M -1.40311M -1.08258M -1.20268M -0.54561M
Other operating expenses 1.89M 1.45M 1.08M 1.47M 0.55M
Interest expense 0.11M 0.05M 0.00414M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.00008M 0.00000M 0.00006M 0.00013M -
Net interest income -0.11015M -0.04968M -0.00408M 0.00013M -
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense - 0.05M 0.00414M 0.00624M 0.00000M
Total revenue 0.15M 0.04M 0.00000M 0.26M 0.00000M
Total operating expenses 1.89M 1.45M 1.08M 1.47M 0.55M
Cost of revenue - - - - 0.00000M
Total other income expense net -0.11023M -0.00111M -0.00747M -0.00636M -0.01875M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -1.84223M -1.45390M -1.09419M -1.21528M -0.54561M
Net income applicable to common shares - -1.45390M -1.09419M -1.21528M -0.54561M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 1.09M 0.73M 1.47M 0.95M 0.64M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.00000M - - - -
Total liab 1.70M 1.88M 2.11M 1.03M 1.08M
Total stockholder equity -0.60961M -1.14958M -0.63569M -0.07909M -0.43913M
Deferred long term liab - - - - -
Other current liab 0.00834M 1.65M 1.83M 0.89M 0.96M
Common stock 10.14M 8.24M 7.12M 6.88M 5.43M
Capital stock 10.14M 8.24M 7.12M 6.88M 5.43M
Retained earnings -13.45043M -11.97827M -10.11793M -8.59061M -7.49642M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.16M 0.07M 0.38M 0.88M 0.61M
Cash and equivalents - - - - -
Total current liabilities 1.24M 1.66M 1.50M 0.92M 1.08M
Current deferred revenue 0.00834M 0.01M 0.01M - -
Net debt 0.65M 0.75M 0.67M -0.75835M -0.60314M
Short term debt 1.09M 0.61M 0.44M 0.00971M 0.00866M
Short long term debt - 0.33M 0.14M - -
Short long term debt total 0.81M 0.82M 1.05M 0.12M 0.00866M
Other stockholder equity 2.70M 2.59M 2.36M 1.64M 1.62M
Property plant equipment - - 0.97M 0.03M 0.00937M
Total current assets 0.20M 0.13M 0.50M 0.92M 0.63M
Long term investments 0.00320M 0.00320M 0.00320M 0.00320M -
Net tangible assets - - -0.63569M -0.07909M -0.43913M
Short term investments - - - - -
Net receivables 0.04M 0.03M 0.08M 0.03M 0.02M
Long term debt - - 0.10M 0.09M -
Inventory - - - - -
Accounts payable 0.14M 0.22M 0.13M 0.03M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.35M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.01M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.89M 0.61M 0.97M 0.03M 0.00937M
Capital lease obligations 0.81M 0.50M 0.81M 0.03M 0.00866M
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.00530M -0.05920M -0.00320M -0.00320M -0.00320M
Change to liabilities - 0.11M -0.08206M -0.05208M 0.00346M
Total cashflows from investing activities - -0.05920M -0.00320M -0.00079M -0.00079M
Net borrowings - -0.12914M 0.02M 0.17M 0.04M
Total cash from financing activities 0.61M 0.77M 0.72M 1.05M 0.26M
Change to operating activities - -0.01599M -0.01817M -0.07168M 0.26M
Net income -1.84223M -1.45390M -1.09419M -1.21528M -0.54561M
Change in cash -0.31067M -0.49497M 0.27M 0.59M -0.01664M
Begin period cash flow 0.38M 0.88M 0.61M 0.02M 0.04M
End period cash flow 0.07M 0.38M 0.88M 0.61M 0.02M
Total cash from operating activities -0.91442M -1.20393M -0.45555M -0.45378M -0.27784M
Issuance of capital stock 0.96M - - 0.71M 0.22M
Depreciation 0.39M 0.18M 0.01M 0.01M 0.01M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - -0.05496M -0.01105M -0.00355M 0.00070M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 0.03M 1.08M 0.74M 0.35M 0.04M
Change to netincome - 0.03M 0.38M 0.88M 0.00203M
Capital expenditures 0.00530M 0.06M 0.06M 0.00079M 0.00079M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital 0.14M 0.04M 0.24M -0.12730M 0.27M
Stock based compensation 0.33M 0.00000M 0.40M 0.86M 0.00203M
Other non cash items 0.07M 0.03M -0.01101M 0.02M -
Free cash flow -0.91972M -1.26313M -0.45555M -0.45458M -0.27784M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMKDF
BioMark Diagnostics Inc		 - -% 0.19 - - 123.90 - 133.22 -8.8335
TMO
Thermo Fisher Scientific Inc		 -0.22 0.05% 411.84 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.475 0.24% 195.63 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -0.69 0.61% 113.08 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 1.85 0.36% 519.95 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

BioMark Diagnostics Inc

3851 Shell Road, Richmond, BC, Canada, V6X 2W2

Key Executives

Name Title Year Born
Mr. Rashid Ahmed Maula Bux B.Sc., MBA Founder, CEO, Pres & Director NA
Ms. Guoyu Huang MBA Chief Financial Officer NA
Mr. Brian Kai-Ming Cheng B.Sc., M.Sc, M.Sc. Chief Technical Officer & Independent Director NA
Dr. Jeff Haince Ph.D. GM & Chief Scientific Officer NA
Neal Kaplan Chief Financial Officer of US NA
Dr. Daniel Sitar Principal Scientific Advisor NA
Mr. Rashid Ahmed Maula Bux B.Sc., MBA Founder, CEO, President & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.